---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-23-000027"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:39:26.866568+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics Q2 net loss narrows to $5.1M; cash runway through Q4 2024; WTX-124 data expected 4Q23

## Summary
- Net loss $5.1M ($0.16/diluted share) vs $14.6M ($0.83) in Q2 2022; collaboration revenue $8.1M (up from $4.1M).
- Cash and equivalents $137.5M at June 30, 2023; restricted cash $21.2M; runway through at least Q4 2024.
- R&D expenses fell to $9.6M from $13.9M YoY on lower manufacturing costs and purchase-order closeouts.
- WTX-124 Phase 1/1b enrollment ongoing; initial monotherapy safety, PK, and biomarker data anticipated in 4Q 2023.
- Jazz Pharmaceuticals' JZP898 (formerly WTX-613) IND cleared July 2023 under the Werewolf collaboration.

## SEC filing metadata
- accession: 0001785530-23-000027
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553023000027/0001785530-23-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553023000027/howl-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-23-000027
- JSON: https://secwatch.observer/filing/0001785530-23-000027.json
- Plain text: https://secwatch.observer/filing/0001785530-23-000027.txt

## Key facts
- Earnings Releases
  Werewolf Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $8.1 million, net income $5.1 million.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $8.1 million
  - Net income: $5.1 million
  - Result: reported results
  source text: Collaboration revenue was $8.1 million for the second quarter of 2023, compared to $4.1 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785530/000178553023000027/0001785530-23-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.